17-AAG

SKU
A-1256
  • CAS:75747-14-7
  • Formula:C31H43N3O8
  • MW:585.7 Da
  • Appearance:Purple Powder
  • Purity:>99%

0

1

0

Starting at $41.54

Product Name Qty
17-AAG
500 ug
$41.54
17-AAG
1 mg
$59.52
17-AAG
5 mg
$154.66

17-AAG (also called Tanespimycin) is an ansamycin antibiotic which acts as an anti-tumor agent. Specifically, 17-AAG binds and inhibits Hsp90 (Heat shock protein 90). Hsp90 is a protein chaperone that binds to signaling proteins, known as client proteins. These client proteins include key cancer-relevant targets such as mutated p53, Bcr-Abl, Her2, Akt, Raf-1, B-Raf, and others.17-AAG is able to disrupt the Hsp90-client protein complexes and lead to the degradation of the client proteins.

More Information
Alternate Name/Synonyms
Tanespimycin; 17-Allylaminogeldanamycin;
SKU
A-1256
CAS #
75747-14-7
Chemical Name
[(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-enylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
Chemical Formula
C31H43N3O8
Molecular Weight
585.7 Da
Appearance
Purple Powder
Purity
>99%
Solubility
DMSO, Methanol: Clear purple solution at 10 mg/ml
Melting Point
207-208°C
Preparation
N/A
Storage Temp
-20°C
THERAPEUTIC AREA
Oncological Disorders
USE
For research use only. Not intended for diagnostic or therapeutic use. 17-AAG is a derivative of the antibiotic geldanamycin that is being studied in the treatment of cancer, specifically in younger patients with certain types of leukemia or solid tumors, especially kidney tumors. It works by inhibiting Hsp90, which is expressed in those tumors.
Merck Index
N/A
MDL NUMBER
MFCD04973892
CHEMACX
X1367336-8
INCHI
InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10-,20-15-/t17-,19+,24+,25+,27-,29+/m1/s1
SMILES
C[C@H]1C[C@@H]([C@@H]([C@H](/C=C([C@@H]([C@H](/C=CC=C(/C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)/C)C)O)OC
RTECS
Not Applicable
UN #'S
Not Applicable
Handling
Avoid contact with skin, eyes or clothing. Use personal protective equipment as required. Wash contaminated clothing before reuse. Do not breathe dust/fume/gas/mist/vapors/spray. Do not eat, drink or smoke when using this product. Use with local exhaust ventilation
Citations
CLINICAL INVESTIGATIONS: Pharmacokinetic Assessment of the Uptake of 16β-18F-Fluoro-5-Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET Bradley J. Beattie, Peter M. Smith-Jones, Yuliya S. Jhanwar, Heiko Schöder, C. Ross Schmidtlein, Michael J. Morris, Pat Zanzonico, Olivia Squire, Gustavo S.P. Meirelles, Ron Finn, Mohammad Namavari, Shangde Cai, Howard I. Scher, Steven M. Larson, and John L. Humm J. Nucl. Med., Feb 2010; 51: 183 - 192.
Citations_Hyperlink
http://jnm.snmjournals.org/content/51/2/183.full.pdf+html
Certificate of Analysis 1
Certificate of Analysis 2
Certificate of Analysis 3
Handling Avoid contact with skin, eyes or clothing. Use personal protective equipment as required. Wash contaminated clothing before reuse. Do not breathe dust/fume/gas/mist/vapors/spray. Do not eat, drink or smoke when using this product. Use with local exhaust ventilation
UN #'S Not Applicable
Citations Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET
Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation
Hyperglycaemic conditions perturb mouse oocyte in vitro developmental competence via beta-O-linked glycosylation of heat shock protein 90
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C
Akt and CHIP coregulate tau degradation through coordinated interactions
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models
Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis
Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin
Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90)
The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells
CXCL1 inhibits airway smooth muscle cell migration through the decoy receptor Duffy antigen receptor for chemokines
Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling
Regulation of proto-oncogenic dbl by chaperone-controlled, ubiquitin-mediated degradation
Protein Kinase Cα (PKCα) Is Resistant to Long Term Desensitization/Down-regulation by Prolonged Diacylglycerol Stimulation
Plekhg4 is a novel Dbl family guanine nucleotide exchange factor protein for rho family GTPases
Regulated binding of importin-α to protein kinase Cδ in response to apoptotic signals facilitates nuclear import
The chaperones Hsp90 and Cdc37 mediate the maturation and stabilization of protein kinase C through a conserved PXXP motif in the C-terminal tail
The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells
Dual induction of PKR with E2F-1 and IFN-alpha to enhance gene therapy against hepatocellular carcinoma
VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer
Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells
Efficacy of barriers and hypoxia-inducible factor inhibitors to prevent CO(2) pneumoperitoneum-enhanced adhesions in a laparoscopic mouse model
Cellular growth kinetics distinguish a cyclophilin inhibitor from an HSP90 inhibitor as a selective inhibitor of hepatitis C virus
17-AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of autophagy
Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells
Role of surgeons in clinical trials for thyroid cancer
17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells
Improvement of inhibitor identification for heat shock protein 90α by utilizing a red-shifted fluorescence polarization probe
17AAG-induced internalisation of HER2-specific Affibody molecules
A constraint optimization framework for discovery of cellular signaling and regulatory networks
Development of Chemical Modulators for Heat Shock Protein 70 (Hsp70): a Potential Therapeutic Target for Tauopathies.
Treatment strategies in Acute myelogenous leukemia: Investigating Hsp90 and p53 as targets
Heat Shock Protein 90 Regulates Angiotensin II-induced Vascular Smooth Muscle Cell Hypertrophy through STAT1 Nuclear Translocation and IL-6 Release
Mechanisms that regulate the maturation and down-regulation of protein kinase C
Consequences of the Interaction between IL-17 Cytokines and Airway Smooth Muscle Cells in the Pathogenesis of Airway Remodeling in Asthma
Immune expression and inhibition of heat shock protein 90 in uveal melanoma
Proteomic analysis of waldenstrom macroglobulinemia
Regulation of Dbl Family Guanine Nucleotide Exchange Factors
We found other products you might like!
To Top